Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial

OBJECTIVE: To assess the efficacy and safety of pyrotinib (an irreversible pan-HER (human epidermal growth factor receptor) inhibitor), trastuzumab, and docetaxel compared with placebo, trastuzumab, and docetaxel for untreated HER2 positive metastatic breast cancer. DESIGN: Randomised, double blind,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Fei, Yan, Min, Li, Wei, Ouyang, Quchang, Tong, Zhongsheng, Teng, Yuee, Wang, Yongsheng, Wang, Shusen, Geng, Cuizhi, Luo, Ting, Zhong, Jincai, Zhang, Qingyuan, Liu, Qiang, Zeng, Xiaohua, Sun, Tao, Mo, Qinguo, Liu, Hu, Cheng, Ying, Cheng, Jing, Wang, Xiaojia, Nie, Jianyun, Yang, Jin, Wu, Xinhong, Wang, Xinshuai, Li, Huiping, Ye, Changsheng, Dong, Fangli, Wu, Shuchao, Zhu, Xiaoyu, Xu, Binghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616786/
https://www.ncbi.nlm.nih.gov/pubmed/37907210
http://dx.doi.org/10.1136/bmj-2023-076065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616786/
https://www.ncbi.nlm.nih.gov/pubmed/37907210
http://dx.doi.org/10.1136/bmj-2023-076065

Ejemplares similares